Loading
A phase 1/2 trial of AZD5335, Saruparib, Bevacizumab in ovarian cancer and endometrial cancer, run by AstraZeneca, now recruiting.
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors is a phase 1/2 interventional study registered as NCT05797168 by AstraZeneca, with 602 participants planned, started 2023-06-05 and due to reach its primary completion in 2028-08-04. Interventions recorded: Torvutatug samrotecan, Saruparib, Bevacizumab, Carboplatin, Palacaparib. Conditions listed: Ovarian Cancer, Lung Adenocarcinoma, Endometrial Cancer, Lung Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.
Shares Palacaparib, Saruparib, Endometrial cancer, AstraZeneca.
Shares AZD5335, AstraZeneca, Ovarian cancer.
Shares Palacaparib, AstraZeneca.
Shares Saruparib, AstraZeneca, Carboplatin, Ovarian cancer.
Shares Saruparib, AstraZeneca.
Shares Saruparib, AstraZeneca.
Shares Saruparib, AstraZeneca.
Shares Palacaparib, AstraZeneca.